Novel positive Inotropic drugs in the treatment of heart failure

A tétel rövid nézete
dc.contributor.advisorPriksz, Dániel
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.contributor.authorMatlik, Zeina
dc.contributor.departmentDE--Általános Orvostudományi Karhu_HU
dc.contributor.opponentGyöngyösi, Alexandra
dc.contributor.opponentKozma, Mariann
dc.contributor.opponentdeptDebreceni Egyetem::Gyógyszerésztudományi Kar::Gyógyszerhatástani Tanszékhu_HU
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.date.accessioned2021-09-16T09:52:47Z
dc.date.available2021-09-16T09:52:47Z
dc.date.created2021
dc.description.abstractEnd-stage heart failure is a chronic illness with a high death rate, few medical treatment options, and limited resources. For decades, long term use of inotropes have been essential in the treatment of acute cardiogenic shock. While inotropes increase cardiac output, they are associated with an increased risk of death due to tachycardia and increased oxygen consumption. Inotropes are currently used to improve cardiac activity by amplifying normal calcium entry pathways into cells, however, this requires a lot of energy, which has negative effects. If this energy was somehow to be conserved, then it could be used to regenerate cells and promote mitochondrial health and reduce oxidative stress. It is hoped that the next generation of inotropic agents would improve myocardial performance without shortening velocity or facilitating unnecessary calcium modulation at the SR or L-type calcium channel level. The arrival of new agents is on the horizon. The procedures used to investigate their protection and effectiveness, on the other hand, may be difficult. On top of that, end stage heart failure patients are inherently complex, posing a slew of additional obstacles. Clinical studies of this patient population are expected to remain costly, complex, and unclear in terms of proper end points. However, despite the many challenges and disappointments, the search for these safer positive inotropic medications has persisted and seems to be succeeding.hu_HU
dc.description.courseáltalános orvoshu_HU
dc.description.courselangangolhu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent32hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/321794
dc.language.isoenhu_HU
dc.subjectpharmacologyhu_HU
dc.subjectcardiology
dc.subject.dspaceDEENK Témalista::Orvostudományhu_HU
dc.titleNovel positive Inotropic drugs in the treatment of heart failurehu_HU
Fájlok
Gyűjtemények
Theses (Faculty of Medicine)